Akebia Ther (AKBA) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Over the past 4 years, Akebia Ther has achieved a revenue compound annual growth rate (CAGR) of -14.2%, while earnings have grown at -34.8% CAGR.
Historical revenue and profitability trends for Akebia Ther
The chart above illustrates Akebia Ther's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of Akebia Ther's business.
How efficiently Akebia Ther converts revenue into profit
Profit margins reveal how much of each dollar of revenue Akebia Ther retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project Akebia Ther to continue focusing on sustainable operations. The consensus analyst rating is 4.75 based on 4 analysts.
Based on our comprehensive analysis, Akebia Ther (AKBA) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of Akebia Ther's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how Akebia Ther stacks up against similar companies
Explore growth analysis for top stocks
Related: AKBA Valuation, AKBA Dividend, AKBA Financial Health
Compare: AKBA vs AAPL, AKBA vs MSFT, AKBA vs GOOGL